Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells
Top Cited Papers
- 12 October 2016
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 8 (360), 360ra134
- https://doi.org/10.1126/scitranslmed.aaf9336
Abstract
Genetic diseases of blood cells are prime candidates for treatment through ex vivo gene editing of CD34+ hematopoietic stem/progenitor cells (HSPCs), and a variety of technologies have been proposed to treat these disorders. Sickle cell disease (SCD) is a recessive genetic disorder caused by a single-nucleotide polymorphism in the β-globin gene (HBB). Sickle hemoglobin damages erythrocytes, causing vasoocclusion, severe pain, progressive organ damage, and premature death. We optimize design and delivery parameters of a ribonucleoprotein (RNP) complex comprising Cas9 protein and unmodified single guide RNA, together with a single-stranded DNA oligonucleotide donor (ssODN), to enable efficient replacement of the SCD mutation in human HSPCs. Corrected HSPCs from SCD patients produced less sickle hemoglobin RNA and protein and correspondingly increased wild-type hemoglobin when differentiated into erythroblasts. When engrafted into immunocompromised mice, ex vivo treated human HSPCs maintain SCD gene edits throughout 16 weeks at a level likely to have clinical benefit. These results demonstrate that an accessible approach combining Cas9 RNP with an ssODN can mediate efficient HSPC genome editing, enables investigator-led exploration of gene editing reagents in primary hematopoietic stem cells, and suggests a path toward the development of new gene editing treatments for SCD and other hematopoietic diseases.Keywords
Funding Information
- Li Ka Shing Foundation
- Siebel Scholars Fund at Berkeley
- NIH (R01 GM078571, 5R21AA022753, 1R56ES022377-01)
- Jordan Family Fund
- Doris Duke Charitable Foundation
This publication has 58 references indexed in Scilit:
- CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activityNucleic Acids Research, 2013
- Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENsBiotechnology & Bioengineering, 2013
- RNA-programmed genome editing in human cellseLife, 2013
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genomeBMC Bioinformatics, 2011
- In vivo genome editing restores haemostasis in a mouse model of haemophiliaNature, 2011
- Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysisBritish Journal of Haematology, 2007
- The effect of fetal hemoglobin on the survival characteristics of sickle cellsBlood, 2006
- The Human Genome Browser at UCSCGenome Research, 2002
- The Inheritance of Sickle Cell AnemiaScience, 1949